|Baseline characteristics of patients with VL and/or malaria recruited at Tabarak Allah Hospital, Sudan|
|Characteristics||Patient group||P value|
|Subjects ( n )||29||21||15||65|
|Male/Female ( n )||20/8a||11/9b||9/6||40/23c||0.5|
|Age (years)||19 (9-29)d||8 (7-26)||16 (9-21)||15 (8-24)e||0.2|
|Hb level (g/dL)||9.6 (7.1-12.4)||10.3 (9.1-11.2)||9.9 (7.5-11.5)||10.0 (8.4-11.4)||0.8|
|WBC count/mm3||5650 (4925-6900)f||6800 (5900-8000)g||5400 (4250-7150)h||6050 (4950-7400)i||0.2|
|DAT titer||25600 (6400-102400)||NA||12800 (6400-102400)||19200 (6400-102400)||0.9†|
|P.f. parasitaemia (parasites/μL)||NA||825 (355-2325)j||53 (38-585)k||370 (51-1113)l||0.005‡|
When not otherwise indicated, data shown represent median and (interquartile range).
Hb = hemoglobin; WBC = white blood cell; DAT = direct agglutination test; P.f. = Plasmodium falciparum; NA = not applicable.
Groups 1 to 3 are: 1 = visceral leishmaniasis patients, 2 = malaria patients, 3 = visceral leishmaniasis-malaria co-infected patients.
The Kruskall-Wallis test was used to calculate the P values, except for the variable sex for which the Chi-Square test was used, and for the variables DAT titer and P.f. parasitaemia, for which the Mann-Whitney test was used.
†P value refers to differences between groups 1 and 3 only.
‡P value refers to differences between groups 2 and 3 only.
Sex data based on a 28 patients b 20 patients c 63 patients. Age data based on d 27 patients and e 63 patients. WBC count data based on f 18 patients, g 11 patients, h 13 patients and i 42 patients. P. falciparum parasitaemia data based on j 12 patients, k 10 patients and l 22 patients. Two co-infected patients received artemether i.m. three weeks prior to diagnosis and their data on P. falciparum parasitaemia were excluded to reduce possible bias.
van den Bogaart et al.
van den Bogaart et al. BMC Immunology 2014 15:16 doi:10.1186/1471-2172-15-16